RT Journal Article
SR Electronic
T1 Antimyelin antibody in multiple sclerosis: no change during immunosuppression
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 872
OP 875
DO 10.1136/jnnp.40.9.872
VO 40
IS 9
A1 Wilkerson, L. D.
A1 Lisak, R. P.
A1 Zweiman, B.
A1 Silberberg, D. H.
YR 1977
UL http://jnnp.bmj.com/content/40/9/872.abstract
AB We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine therapy was not associated with significant change in titres of antimyelin antibody. Variation of titre of antimyelin antibody in apparent association with disease activity continued during therapy. No significant changes occurred in levels of serum immunoglobulins.